Literature DB >> 21631158

Genes, environment, and individual differences in responding to treatment for depression.

Rudolf Uher1.   

Abstract

A principal weakness of evidence-based psychiatry is that it does not account for the individual variability in therapeutic response among individuals with the same diagnosis. The aim of personalized psychiatry is to remediate this shortcoming and to use predictors to select treatment that is most likely to be beneficial for an individual. This article reviews the evidence that genetic variation, environmental exposures, and gene-environment interactions shape mental illness and influence treatment outcomes, with a primary focus on depression. Several genetic polymorphisms have been identified that influence the outcome of specific treatments, but the strength and generalizability of such influences are not sufficient to justify personalized prescribing. Environmental exposures in early life, such as childhood maltreatment, exert long-lasting influences that are moderated by inherited genetic variation and mediated through stable epigenetic mechanisms such as tissue- and gene-specific DNA methylation. Pharmacological and psychological treatments act on and against the background of genetic disposition, with epigenetic annotation resulting from previous experiences. Research in animal models suggests the possibility that epigenetic interventions may modify the impact of environmental stressors on mental health. Gaps in evidence are identified that need to be bridged before knowledge about cause can inform cure in personalized psychiatry.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21631158     DOI: 10.3109/10673229.2011.586551

Source DB:  PubMed          Journal:  Harv Rev Psychiatry        ISSN: 1067-3229            Impact factor:   3.732


  30 in total

Review 1.  Gene-environment interaction in major depression and antidepressant treatment response.

Authors:  Robert Keers; Rudolf Uher
Journal:  Curr Psychiatry Rep       Date:  2012-04       Impact factor: 5.285

2.  Genetic moderation of interpersonal psychotherapy efficacy for low-income mothers with major depressive disorder: implications for differential susceptibility.

Authors:  Dante Cicchetti; Sheree L Toth; Elizabeth D Handley
Journal:  Dev Psychopathol       Date:  2015-02

3.  Individual Differences in Response to Antidepressants: A Meta-analysis of Placebo-Controlled Randomized Clinical Trials.

Authors:  Marta M Maslej; Toshiaki A Furukawa; Andrea Cipriani; Paul W Andrews; Benoit H Mulsant
Journal:  JAMA Psychiatry       Date:  2020-06-01       Impact factor: 21.596

Review 4.  Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments.

Authors:  Sidney H Kennedy; Raymond W Lam; Roger S McIntyre; S Valérie Tourjman; Venkat Bhat; Pierre Blier; Mehrul Hasnain; Fabrice Jollant; Anthony J Levitt; Glenda M MacQueen; Shane J McInerney; Diane McIntosh; Roumen V Milev; Daniel J Müller; Sagar V Parikh; Norma L Pearson; Arun V Ravindran; Rudolf Uher
Journal:  Can J Psychiatry       Date:  2016-08-02       Impact factor: 4.356

5.  Characterization of 3(3,4-dihydroxy-phenyl) propionic acid as a novel microbiome-derived epigenetic modifier in attenuation of immune inflammatory response in human monocytes.

Authors:  Jun Wang; Jennifer Blaze; Fatemeh Haghighi; Seunghee Kim-Schulze; Urdvha Raval; Kyle J Trageser; Giulio Maria Pasinetti
Journal:  Mol Immunol       Date:  2020-07-21       Impact factor: 4.407

Review 6.  Epigenetic mechanisms of depression and antidepressant action.

Authors:  Vincent Vialou; Jian Feng; Alfred J Robison; Eric J Nestler
Journal:  Annu Rev Pharmacol Toxicol       Date:  2012-09-27       Impact factor: 13.820

7.  Facilitation of serotonin signaling by SSRIs is attenuated by social isolation.

Authors:  Elyse C Dankoski; Kara L Agster; Megan E Fox; Sheryl S Moy; R Mark Wightman
Journal:  Neuropsychopharmacology       Date:  2014-07-01       Impact factor: 7.853

8.  COGNITION-CHILDHOOD MALTREATMENT INTERACTIONS IN THE PREDICTION OF ANTIDEPRESSANT OUTCOMES IN MAJOR DEPRESSIVE DISORDER PATIENTS: RESULTS FROM THE iSPOT-D TRIAL.

Authors:  Shefali Miller; Lisa M McTeague; Anett Gyurak; Brian Patenaude; Leanne M Williams; Stuart M Grieve; Mayuresh S Korgaonkar; Amit Etkin
Journal:  Depress Anxiety       Date:  2015-04-27       Impact factor: 6.505

9.  From a state to a trait: Trajectories of state mindfulness in meditation during intervention predict changes in trait mindfulness.

Authors:  Laura G Kiken; Eric L Garland; Karen Bluth; Olafur S Palsson; Susan A Gaylord
Journal:  Pers Individ Dif       Date:  2015-07-01

10.  Screening genetic variability at the CNR1 gene in both major depression etiology and clinical response to citalopram treatment.

Authors:  Marina Mitjans; Alessandro Serretti; Chiara Fabbri; Cristóbal Gastó; Rosa Catalán; Lourdes Fañanás; Bárbara Arias
Journal:  Psychopharmacology (Berl)       Date:  2013-02-14       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.